You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 582 Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern cooperative oncology group (ECOG) performance status subgroups in EMPOWER-Lung 1

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials Completed
582 Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern cooperative oncology group (ECOG) performance status subgroups in EMPOWER-Lung 1
Free

Authors

Citation

Kilickap S, Sezer A, Gümüş M, et al
582 Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Eastern cooperative oncology group (ECOG) performance status subgroups in EMPOWER-Lung 1
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0582

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.